Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Intraoperative Imaging with Indocyanine Green for the Improvement of Functional Outcomes in Patients with Prostate Cancer

Trial Status: active

This phase II trial studies whether using indocyanine green (ICG) for imaging taken during surgery (intraoperative) improves functional outcomes in patients with prostate cancer. A treatment option for prostate cancer that is caught early is a type of surgery called robot-assisted radical prostatectomy (RARP). The surgery uses a robot to help remove the entire prostate gland to get rid of the cancer. There are side effects that can happen after surgery, and these can include problems with sexual function. These problems can affect a person's quality of life in the long term. Intraoperative imaging can be used during RARP to help the surgeon visualize the anatomy near the prostate and guide the surgical procedure. ICG is a special dye that can help visualize blood vessels better which may improve the images captured during intraoperative imaging and help the surgeon avoid certain areas or blood vessels during the RARP. Using ICG for intraoperative imaging may improve functional outcomes in patients with prostate cancer.